Johnson & Johnson (NYSE: JNJ) closed Friday at $234.34, finishing the session up 1.13% — a $2.61 gain — as the healthcare giant continues to build on a strong start to 2026. JNJ is up more than 13% year-to-date, rewarding early-year buyers with double-digit returns so far. What’s driving the momentum Investors are looking ahead to a busy pipeline: J&J has multiple drug launches scheduled through 2027 and stands to benefit from potential U.S. Food and Drug Administration approvals. Those approvals could act as meaningful catalysts for further upside. Short-term friction After reaching a 52-week high of $251, the stock has slipped back toward the $234 area and has traded in a relatively narrow range since April. Broader cooling in healthcare sector buying has contributed to that consolidation. At the same time, J&J remains mired in a wave of U.S. lawsuits, a legal overhang that has kept sentiment cautious and some investors on the sidelines. Analyst view and price target In mid-May, David Risinger, Senior Research Analyst at Leerink Partners, upgraded his rating on JNJ from “hold” to “buy,” maintaining an “Outperform” stance. Risinger called the stock undervalued and pointed to accelerating growth prospects from the upcoming drug launches as justification for the upgrade. Price target and potential returns Leerink’s revised target for JNJ is $265 — about $31 above Friday’s close. If the target is reached, that would imply roughly a 13% gain (turning a $1,000 position into approximately $1,130) from the current price. Bottom line for investors (and crypto traders) For investors — including crypto traders looking to diversify into equities — J&J represents a defensive, pharma-led play with clear upside catalysts (pipeline and FDA approvals) but tangible downside risks (ongoing litigation and near-term rangebound trading). As always, potential rewards should be weighed against the legal and market uncertainties.
J&J Up 13% YTD, Leerink Sets $265 Target as Analyst Upgrades to 'Buy'
ChainGPTShare
Summary
Johnson & Johnson (JNJ) closed at $234.34 on May 23, up 1.13% for the session, with a year-to-date gain of over 13%. Leerink Partners upgraded its rating to 'buy' in mid-May, maintaining 'Outperform' and setting a $265 target, citing drug launches and FDA approvals. The stock has traded in a narrow range since April amid sector cooling and U.S. lawsuits. Meanwhile, BTC as hedge against inflation remains a key focus for investors. Regulatory efforts under CFT (Countering the Financing of Terrorism) continue to shape market dynamics.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.